Emergent Biosolutions (EBS) 41.27 $EBS 23.3% Return Seen

New Post Public Reply Private Reply Replies (0) Message Board

Jun 14, 2016 at 7:15 AM

Emergent Biosolutions (EBS) 41.27 $EBS

23.3% Return Seen to Date on SmarTrend Emergent Biosolutions Call (EBS)
Comtex SmarTrend(R) - Tue Jun 07, 12:22AM CDT
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on March 30th, 2016 at $35.86. In approximately 2 months, Emergent Biosolutions has returned 23.31% as of today's recent price of $44.22.
EBS: 41.27 (-1.03)

Uptrend Call Working As Emergent Biosolutions Stock Rises 20.3% (EBS)
Comtex SmarTrend(R) - Fri May 27, 1:22AM CDT
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on March 30th, 2016 at $35.86. In approximately 2 months, Emergent Biosolutions has returned 20.33% as of today's recent price of $43.15.
EBS: 41.27 (-1.03)

Typhoid Fever Global Clinical Trials Review 2016 - Key Players are Novartis AG, Emergent BioSolutions & Accelovance - Research and Markets
BusinessWire - Thu May 26, 3:52PM CDT
Research and Markets has announced the addition of the "Typhoid Fever Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
EBS: 41.27 (-1.03)

Corporate Directors From Campbell Soup, Cubic, Emergent BioSolutions, MassMutual, and Navient Become NACD Fellows in Q1 2016
GlobeNewswire - Tue May 24, 8:00AM CDT
The National Association of Corporate Directors (NACD) today announced 65 corporate directors who earned NACD Fellowship--The Gold Standard Director Credential--during the first quarter of 2016. These corporate directors serve on the boards of companies such as Campbell Soup Co., Cubic Corp., Delta Dental, Emergent BioSolutions Inc., KeyCorp, MassMutual Financial Group, Navient Corp., Otter Tail Corp., Patterson Cos. Inc., PRA Group Inc., Triple-S Management Corp., and on the corporate boards of other Fortune 100, nonprofit, and private companies.
EBS: 41.27 (-1.03), KEY: 12.08 (-0.17), GTS: 24.49 (-0.07), CUB: 41.63 (-0.20), OTTR: 31.34 (-0.02)

Emergent BioSolutions Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:16PM CDT
-- Q1 2016 financial performance in line with guidance
EBS: 41.27 (-1.03)

Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available
GlobeNewswire - Wed May 04, 3:15PM CDT
Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2016 beginning at 9:00 AM Eastern at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.
EBS: 41.27 (-1.03)

The Zacks Analyst Blog Highlights: MYR Group, Coty, Kellogg, HCA Holdings and Emergent BioSolutions
Zacks Equity Research - Zacks Investment Research - Mon May 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: MYR Group, Coty, Kellogg, HCA Holdings and Emergent BioSolutions
HCA: 77.95 (-1.60), EBS: 41.27 (-1.03), COTY: 26.36 (-0.53), MYRG: 23.69 (-0.41), K: 76.90 (-1.22)

Seattle Genetics (SGEN) Posts Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 1:09PM CDT
Seattle Genetics (SGEN) reported a loss of 15 cents per share, wider than the Zacks Consensus Estimate of a loss of 11 cents.
EBS: 41.27 (-1.03), SGEN: 39.31 (-1.07), AEGR: 1.26 (-0.11)

United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 41.27 (-1.03), UTHR: 110.06 (-1.29), AEGR: 1.26 (-0.11)

Agenus' (AGEN) Q1 Loss Wider than Expected, Revenue Miss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:41AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 37 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents.
AGEN: 4.00 (unch), EBS: 41.27 (-1.03), AEGR: 1.26 (-0.11), GSK: 40.83 (-0.10)

Acorda (ACOR) Q1 Earnings Decline Y/Y, Ampyra in Focus
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 9:50AM CDT
Investor focus will remain on the patent challenges being faced by Acorda's (ACOR) key product, Ampyra.
BIIB: 244.35 (-1.78), EBS: 41.27 (-1.03), BITI: 25.80 (-0.71), ACOR: 26.23 (-0.84)

5 Sturdy Stocks to Play Weakest Growth in 2 Years
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:56AM CDT
Stocks in defensive groups offer a good way to earn some decent returns in this slow growth environment
HCA: 77.95 (-1.60), EBS: 41.27 (-1.03), COTY: 26.36 (-0.53), MYRG: 23.69 (-0.41), K: 76.90 (-1.22)

Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:31AM CDT
Alkermes (ALKS) reported a loss of 32 cents per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 43 cents.
BIIB: 244.35 (-1.78), EBS: 41.27 (-1.03), AEGR: 1.26 (-0.11), ALKS: 42.47 (-0.18)

Gilead (GILD) Lags Q1 Earnings & Revenues, '16 View Intact
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:19AM CDT
Gilead Sciences (GILD) reported lower-than-expected first-quarter 2016 earnings (including stock-based compensation expenses) of $2.98 per share.
EBS: 41.27 (-1.03), GILD: 83.98 (-0.47), MRK: 56.11 (-0.70), AEGR: 1.26 (-0.11)

Alexion (ALXN) Lags Q1 Earnings & Revenues, Revises View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:40PM CDT
Alexion (ALXN) reported earnings of 87 cents per share, below the Zacks Consensus Estimate of 91 cents.
EBS: 41.27 (-1.03), ALXN: 133.32 (-2.29), AEGR: 1.26 (-0.11), ANIK: 49.29 (+0.13)

GlaxoSmithKline (GSK) Q1 Earnings Lag, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 12:06PM CDT
Glaxo (GSK) reported first-quarter 2016 core earnings of 57 cents per American depositary share, missing the Zacks Consensus Estimate of 60 cents.
EBS: 41.27 (-1.03), GSK: 40.83 (-0.10), ANIK: 49.29 (+0.13), NVS: 77.33 (-1.61)

Bristol-Myers (BMY) Tops Q1 Earnings, Updates 2016 View
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:27AM CDT
Bristol-Myers' (BMY) first-quarter 2016 earnings (excluding special items) of 74 cents per share easily beat the Zacks Consensus Estimate of 66 cents.
EBS: 41.27 (-1.03), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), ANIK: 49.29 (+0.13)

Celgene (CELG) Beats on Q1 Earnings, Updates '16 Outlook
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 10:05AM CDT
Celgene Corp. (CELG) reported first-quarter 2016 earnings of $1.18 per share (including share-based compensation expense), beating the Zacks Consensus Estimate of $1.05.
EBS: 41.27 (-1.03), AEGR: 1.26 (-0.11), ANIK: 49.29 (+0.13), CELG: 101.61 (-1.30)

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International, Air Methods and Charles River Laboratories International
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 8:30AM CDT
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Molina Healthcare, PAREXEL International, Air Methods and Charles River Laboratories International
AIRM: 35.45 (-0.73), PRXL: 59.01 (-1.15), EBS: 41.27 (-1.03), CRL: 84.32 (-0.41), MOH: 50.49 (-0.24)

Perrigo's CEO Resigns, Trims 2016 Outlook, Stock Tumbles
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 12:36PM CDT
Perrigo Company (PRGO) shares tumbled 18% after the Chairman and CEO Joseph Papa resigned and the company lowered its earnings guidance for 2016.
VRX: 23.78 (-0.36), PRGO: 99.06 (+0.55), EBS: 41.27 (-1.03), GILD: 83.98 (-0.47)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

New American Funding Expands in Carolinas with Mullinix Move

The Gathering of Mortgage Titans You don't just waltz into the mortgage world with a $2 billion track record and expect folks not to notice. Will Mullinix, a name that's become synonymous in the Carolinas with mortgage mastery, has decided to bring his influential Mullinix Mortgage Group under the banner of New American Funding. Talk about a power play. This bold strategy...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

VetsinTech's AI Training Boosts Military Careers

A New Spin on Engineering Careers Sometimes it feels like every corner I turn in this market maze, there’s something about AI. It’s not just chirping in the tech world anymore; it’s banging on the doors of sectors like engineering, aerospace, and manufacturing. And now, VetsinTech is tossing its hat into the AI ring with a fresh program aimed at blending military...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

OmniActive's Fenavari: A New Era in Women's Health

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...